t
ImmuPharma PLC announced on 01 September 2025 the promotion of Dr Sébastien Goudreau to Chief Scientific Officer. Dr Laura Mauran-Ambrosino was also promoted to Head of Research and Development. These appointments were made in conjunction with the filing of a new patent application for the company's lead asset, P140.
| Date | 1 Sept 2025 |
| Time | 14:12:05 |
| Category | Miscellaneous |
| ID | 5047X |
ImmuPharma PLC
("ImmuPharma" or the "Company")
Appointments of Chief Scientific Officer and Head of R&D
ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces key appointments, in conjunction with the filing of a groundbreaking new patent application for its lead asset P140, separately announced today.
Recognising the significance of this major step forward, Dr Sébastien Goudreau has been promoted into the position of Chief Scientific Officer and Dr Laura Mauran-Ambrosino has been promoted to Head of Research and Development, of the Company.
Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said:
"The new patent on P140 is a major step forward for the Company and is the result of the impressive and dedicated research conducted by both by Sébastien and Laura over the last two years.
As we continue to move forward on the next step of our corporate journey, which is the partnering and commercialisation of our product portfolio, P140 in particular, it is important that our R&D team is at the forefront of our interactions and negotiations with current and future commercial partners.
I and the Board congratulate both Sébastien and Laura on their new appointments and thank them for their innovation and hard work."
Ends
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk.
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.